Wall Street Zen Downgrades NewAmsterdam Pharma (NASDAQ:NAMS) to Sell

Wall Street Zen lowered shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) from a hold rating to a sell rating in a report issued on Saturday.

NAMS has been the subject of a number of other research reports. Cantor Fitzgerald began coverage on NewAmsterdam Pharma in a research report on Wednesday, June 4th. They set an "overweight" rating and a $42.00 price objective for the company. Needham & Company LLC reissued a "buy" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a research report on Monday, March 3rd. Citigroup initiated coverage on shares of NewAmsterdam Pharma in a research note on Tuesday, June 17th. They issued a "buy" rating and a $42.00 price target on the stock. Finally, Scotiabank lifted their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $42.89.

NewAmsterdam Pharma Trading Up 1.0%

NewAmsterdam Pharma stock traded up $0.19 on Friday, hitting $18.40. 882,835 shares of the stock traded hands, compared to its average volume of 701,037. The business's fifty day simple moving average is $18.54 and its 200 day simple moving average is $20.84. The firm has a market cap of $2.07 billion, a P/E ratio of -9.79 and a beta of -0.03. NewAmsterdam Pharma has a 1 year low of $14.06 and a 1 year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. The business had revenue of $2.98 million for the quarter, compared to the consensus estimate of $1.46 million. As a group, analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director James N. Topper bought 8,584 shares of the company's stock in a transaction on Monday, June 16th. The shares were acquired at an average cost of $19.50 per share, with a total value of $167,388.00. Following the completion of the transaction, the director now owns 3,022,153 shares of the company's stock, valued at approximately $58,931,983.50. This trade represents a 0.28% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Douglas F. Kling sold 100,000 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $19.29, for a total transaction of $1,929,000.00. Following the completion of the transaction, the chief operating officer now owns 44,000 shares in the company, valued at $848,760. The trade was a 69.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. 20.84% of the stock is currently owned by insiders.

Institutional Trading of NewAmsterdam Pharma

Hedge funds have recently bought and sold shares of the stock. Quarry LP bought a new position in shares of NewAmsterdam Pharma during the 1st quarter valued at approximately $25,000. GF Fund Management CO. LTD. purchased a new position in NewAmsterdam Pharma during the fourth quarter valued at approximately $50,000. National Bank of Canada FI bought a new position in shares of NewAmsterdam Pharma in the fourth quarter worth approximately $51,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of NewAmsterdam Pharma by 19.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after purchasing an additional 596 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of NewAmsterdam Pharma by 130.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock worth $123,000 after purchasing an additional 3,390 shares in the last quarter. Institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.